293 related articles for article (PubMed ID: 29998375)
1. Microenvironmental derived factors modulating dendritic cell function and vaccine efficacy: the effect of prostanoid receptor and nuclear receptor ligands.
Raaijmakers TK; Ansems M
Cancer Immunol Immunother; 2018 Nov; 67(11):1789-1796. PubMed ID: 29998375
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy.
Zhu S; Yang N; Wu J; Wang X; Wang W; Liu YJ; Chen J
Pharmacol Res; 2020 Sep; 159():104980. PubMed ID: 32504832
[TBL] [Abstract][Full Text] [Related]
3. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies.
Galati D; Zanotta S
Cytotherapy; 2018 Nov; 20(11):1309-1323. PubMed ID: 30360963
[TBL] [Abstract][Full Text] [Related]
4. Harnessing dendritic cells in cancer.
Apetoh L; Locher C; Ghiringhelli F; Kroemer G; Zitvogel L
Semin Immunol; 2011 Feb; 23(1):42-9. PubMed ID: 21295491
[TBL] [Abstract][Full Text] [Related]
5. Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours.
Huang FP; Chen YX; To CK
Eur J Immunol; 2011 Jan; 41(1):18-25. PubMed ID: 21182072
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
7. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
8. The role of dendritic cells in cancer.
Lee YS; Radford KJ
Int Rev Cell Mol Biol; 2019; 348():123-178. PubMed ID: 31810552
[TBL] [Abstract][Full Text] [Related]
9. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.
Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE
Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588
[TBL] [Abstract][Full Text] [Related]
10. Dendritic Cells and Cancer Immunity.
Gardner A; Ruffell B
Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
[TBL] [Abstract][Full Text] [Related]
11. Optimizing dendritic cell-based immunotherapy for cancer.
Zhong H; Shurin MR; Han B
Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
[TBL] [Abstract][Full Text] [Related]
12. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
Ramachandran M; Dimberg A; Essand M
Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
[TBL] [Abstract][Full Text] [Related]
13. Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs.
Truxova I; Pokorna K; Kloudova K; Partlova S; Spisek R; Fucikova J
Immunol Lett; 2014 Jul; 160(1):39-49. PubMed ID: 24726860
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-based vaccine research against cancer.
Mody N; Dubey S; Sharma R; Agrawal U; Vyas SP
Expert Rev Clin Immunol; 2015 Feb; 11(2):213-32. PubMed ID: 25467734
[TBL] [Abstract][Full Text] [Related]
15. β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses.
Ning Y; Xu D; Zhang X; Bai Y; Ding J; Feng T; Wang S; Xu N; Qian K; Wang Y; Qi C
Int J Cancer; 2016 Jun; 138(11):2713-23. PubMed ID: 26773960
[TBL] [Abstract][Full Text] [Related]
16. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
Saxena M; Bhardwaj N
Trends Cancer; 2018 Feb; 4(2):119-137. PubMed ID: 29458962
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.
Homma S; Sagawa Y; Ito M; Ohno T; Toda G
Clin Exp Immunol; 2006 Apr; 144(1):41-7. PubMed ID: 16542363
[TBL] [Abstract][Full Text] [Related]
19. Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses.
Seyfizadeh N; Muthuswamy R; Mitchell DA; Nierkens S; Seyfizadeh N
Crit Rev Oncol Hematol; 2016 Nov; 107():100-110. PubMed ID: 27823637
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.
Schreibelt G; Tel J; Sliepen KH; Benitez-Ribas D; Figdor CG; Adema GJ; de Vries IJ
Cancer Immunol Immunother; 2010 Oct; 59(10):1573-82. PubMed ID: 20204387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
